Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-06-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification released via RNS (London Stock Exchange news service) dated June 1, 2022. The content explicitly states it is a notification made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, detailing the total number of voting rights (1,549,470,612) as of May 31, 2022. This type of regulatory disclosure regarding the total number of shares and voting rights falls under general regulatory announcements. While it relates to capital structure, it is not a financing event (CAP) or a share transaction (POS/SHA), but rather a mandatory periodic disclosure. Since it is a standard regulatory announcement provided via RNS that doesn't fit the more specific categories like DVA (Voting Results) or DIRS (Director's Dealing), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (2770 chars), but it is a direct regulatory filing, not an announcement *about* a report.
2022-06-01 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, submitted to the SEC. It reports a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the sale of American Depositary Shares by the CFO and Director. The content focuses on insider share transactions and complies with EU Market Abuse Regulation disclosure requirements. There are no financial statements, earnings data, or management discussion. The document is a notification of insider share dealings, which corresponds to the category 'Director's Dealing' (DIRS). The document length is 4448 characters, which is sufficient to contain the full notification details rather than just an announcement. Therefore, the classification is DIRS with high confidence.
2022-05-20 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification disseminated via RNS (RNS Number: 3064M) concerning a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR). Specifically, it details the sale of American Depositary Shares (ADSs) by the Chief Financial Officer, Aradhana Sarin. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of 'Director's Dealing'. The presence of the RNS header and the specific nature of the transaction confirm this classification over general regulatory filings (RNS) or capital changes (SHA/POS).
2022-05-20 English
APPOINTMENT OF JOINT CORPORATE BROKERS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content announces the appointment of joint corporate brokers effective May 9, 2022. The document is short (2718 characters) and primarily serves as an announcement rather than a detailed financial or management report. It does not contain financial statements, management discussion, or detailed regulatory information. The nature of the content is an update on corporate broker appointments, which relates to capital markets activities but is not a financing update or capital structure change per se. Given the document's nature as a regulatory announcement without substantive financial data or detailed report content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-09 English
Appointment of joint corporate brokers
Regulatory Filings Classification · 98% confidence The document is a short announcement released via RNS (London Stock Exchange news service) on May 9, 2022. The content explicitly announces the 'Appointment of joint corporate brokers' (Morgan Stanley and J.P. Morgan). This type of announcement, which details changes in key professional advisors or service providers, does not fit neatly into the specific categories like Earnings Release (ER), Annual Report (10-K), or Director's Dealing (DIRS). Since it is a general regulatory announcement distributed through the RNS system and doesn't fit a more specific category (like MANG for board changes, or CAP for financing), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (2297 chars) and it is a direct announcement, not a link to a larger report.
2022-05-09 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filing by AstraZeneca PLC, reporting a transaction in the company's American Depositary Shares by a Non-Executive Director, Andreas Rummelt. The content details a director's sale of shares, including quantity, price, and transaction date. This matches the definition of a Director's Dealing report, which involves personal share transactions by company directors and executives. The document is not an annual or quarterly report, nor an announcement of voting results or capital changes. It is a regulatory filing specifically reporting insider share transactions, fitting the Director's Dealing (DIRS) category.
2022-05-06 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.